Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 914-920

  Georgoulias, Vassilis ^a   Kouroussis, Charalambos ^a   Androulakis, Nikos ^a   Kakolyris, Stelios ^a   Dimopoulos, Meletios Athanasios ^a   Papadakis, Emmanuel ^a   Bouros, Dimosthenis ^a   Apostolopoulou, Fotini ^a   Papadimitriou, Christos ^a   Agelidou, Athina ^a   Hatzakis, Kostas ^a   Kalbakis, Kostas ^a   Kotsakis, Athanasios ^a   Vardakis, Nikos ^a   Vlachonicolis, John ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR GROWTH;

EID: 0033014303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.914     Document Type: Article

References (51)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials - Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
2. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993
4. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
5. Ringel I, Orwitz SB: Studies with PR-56976 (Taxotere): A semi-synthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
6. Ranson MR, Jayson G, Perkins S, et al: Single-agent paclitaxel in advanced non-small cell lung cancer: Single-center phase 11 study using a 3-hour administration schedule. Semin Oncol 24:S6-S9, 1997 (suppl 12)
7. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
8. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
9. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387, 1994
10. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232-1237, 1997
11. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
12. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
13. Kunitah H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 14:1649-1655, 1996
14. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
15. Burris HA, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12:335, 1993 (abstr)
16. Grandara DR, Vokes E, Green M, et al: Docetaxel (Taxotere) in platinum-treated non-small-cell lung cancer: Confirmation of prolonged survival in a multicenter study. Proc Am Soc Clin Oncol 16:454, 1997 (abstr)
17. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
18. Plunket W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15, 1996 (suppl 10)
19. Storniolo AM, Allerheiligen SRB, Pearce HL: Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 24:2-7, 1997 (suppl 7)
20. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
21. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
22. Burkes RL, Shepherd FA: Gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol 6:S57-S60, 1995 (suppl 3)
23. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996
24. Fossella FV, Lippman SM, Shin DM, et al: Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15:310-316, 1997
25. Androulakis N, Kouroussis C, Kakolyris S, et al: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study. Ann Oncol 9:331-334, 1998
26. Poole CJ, Cook J, Hogberg T, et al: A phase I trial of gemcitabine and paclitaxel in patients with recurrent epithelial ovarian cancer. Ann Oncol 7:341P, 1996 (suppl, abstr)
27. Poole CJ, Perren T, Hogberg T, et al: A phase I study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma. Eur J Cancer 33:543, 1997 (suppl 8) (abstr)
28. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
29. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1959
30. Cox DR: The Analysis of Binary Data. London, United Kingdom, Methuen, 1970
31. Hennequin C, Giocanti N, Favaudon V: S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71:1194-1198, 1995
32. Donnadieu N, Paesmans M, Sculier JP, et al: Chemotherapy of non-small cell lung cancer according to disease extent: A meta-analysis of the literature. Lung Cancer 7:243-252, 1991
33. Rapp E, Pater JK, Wellan A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
34. Rowinsky EK, Chaudhry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
35. Georgiadis MS, Schuler B, Johnson BE: Four-day paclitaxel infusion with cisplatin for patients with lung cancer. Semin Oncol 22:63-66, 1995 (suppl 9)
36. Sorensen JB, Wedernang K, Dombernowsky P: Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin Oncol 24:S18-S20, 1997 (suppl 12)
37. Von Pawel J, Wagner H, Niederle N, et al: Phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin Oncol 23:47-50, 1996 (suppl 16)
38. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis. J Clin Oncol 13:1860-1870, 1995
39. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996
40. Hainsworth JD, Urba WJ, Hon JK, et al: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small-cell lung cancer: Results of a multicentre, phase II trial. Eur J Cancer 34:654-658, 1998
41. Zalcberg J, Millward M, Bishop J, et al: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953, 1998
42. Georgoulias V, Androulakis N, Dimopoulos MA, et al: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. Ann Oncol 9:331-334, 1998
43. Berille J, Le Chevalier T, Zalcberg JR, et al: Overview on Taxotere-cisplatin (TXT/CDDP) combination in non-small-cell lung cancer (NSCLC). Ann Oncol 7:90, 1996 (suppl 5, abstr)
44. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: Preliminary results. Semin Oncol 23:43-47, 1996 (suppl 10)
45. Shepherd FA, Burkes R, Cormier Y, et al: Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose. J Clin Oncol 14:1656-1662, 1996
46. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
47. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997
48. Sanchez-Rovira P, Mohedano N, Moreno MA, et al: Preliminary results from an early phase II combination of gemcitabine and taxol in metastatic breast cancer. Eur J Cancer 33:685, 1997 (suppl 8, abstr)
49. Weick JK, Crowley J, Natale RB, et al: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 9:1157-1162, 1991
50. Cullen MH, Joshi R, Chetiyawardana AD, et al: Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58:359-361, 1998
51. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994